Recent years have witnessed major advances that have improved outcome of adults with
acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual …

Abstract The Philadelphia (Ph) chromosome, resulting from the t (9; 22)(q34; q11)
translocation, can be found in chronic myeloid leukemia (CML) as well as in a subset of …

Background Outcomes in patients with Philadelphia chromosome (Ph)–positive acute
lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors …

Background The combination of chemotherapy and ponatinib in Philadelphia chromosome-
positive acute lymphoblastic leukaemia has the potential to be a new standard of care for the …

Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with a bimodal distribution.
The progresses made in understanding its biology led to the development of targeted …

Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …

In the past decade, the available treatments for patients with acute lymphoblastic leukemia
(ALL) have rapidly expanded, in parallel with an increased understanding of the genomic …

The GIMEMA LAL1509 protocol, designed for adult (≥ 18-60 years) de novo Philadelphia
chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) patients, was based on …

Traditional treatment regimens for adult acute lymphoblastic leukemia, including allogeneic
hematopoietic cell transplantation, result in an overall survival of approximately 40%, a …

Novel treatment strategies are needed for the treatment of Philadelphia chromosome–
positive (Ph+) acute lymphoblastic leukemia (ALL) in older patients. This trial evaluated the …